| 摘要 |
<p>Compounds of formula (I), wherein X1 is a -NR1R2 or -OR2 group; each of g2, g3, g4, g5, g6, w2, w3, w4, w5 and w6, which are the same or different, is hydrogen, a halogen atom, (C1-4) alkyl, (C1-4) alkoxy, trifluoromethyl, nitro or (C1-4) alkylthio, with the proviso that at least one of substituents g2, g3, g4, g5, g6 and at least one of substituents w2, w3, w4, w5 and w6 is other than hydrogen; R1 is hydrogen or (C1-4) alkyl; R2 is a non-aromatic (C3-15) carbocyclic radical optionally substituted one or more times by a substituent selected from a halogen atom, (C1-4) alkyl or (C1-4) alkoxy; R3 is hydrogen or a -CH2-R6 group; each of R4 and R5 is independently hydrogen, (C1-4) alkyl or trifluoromethyl; or R4 is hydrogen and R5 and w6 together form an ethylene or trimethylene radical; R6 is hydrogen or, when substituents g2, g3, g4, g5 and/or g6 are not (C1-4) alkyl, R6 is hydrogen, (C1-4) alkyl, fluorine, hydroxy, (C1-5) alkoxy, (C1-5) alkylthio, hydroxy (C1-5) alkoxy, cyano, (C1-5) alkylsulphinyl or (C1-5) alkylsulphonyl; and salts thereof; a method for preparing same and pharmaceutical compositions containing said compounds, are disclosed. Said compounds have excellent CB2 receptor affinity.</p> |
